Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SCH 721015 with SCH 209702 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| SCH 721015 with SCH 209702 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| SCH 721015 with SCH 209702 | GENETIC | Each subject receives a single intravesical administration of SCH 721015 with SCH 209702 at dose levels of 1 x 10\^9 to 3 x 10\^11 particles/mL (based on assessment of tolerability, intermediate dose levels may be used). |
Inclusion Criteria: * Histologically proven recurrent transitional cell carcinoma of the bladder, Stage Tis, Ta. * Patients with recurrent T1 disease who do not wish to have cystectomy. * Subjects must have failed at least two prior courses of BCG with or without recombinant interferon alpha admini...
SCH 721015 with SCH 209702 is an investigational gene therapy being studied for the treatment of bladder neoplasms, specifically transitional cell carcinoma of the bladder. It is in Phase 1 clinical development and has not been approved by the FDA.
SCH 721015 with SCH 209702 is being developed by Merck & Company, Inc., which is publicly traded under the ticker symbol MRK on the New York Stock Exchange.
SCH 721015 with SCH 209702 is in Phase 1 clinical development. It is an investigational gene therapy for bladder neoplasms and is not yet approved for commercial use.
SCH 721015 with SCH 209702 has one completed Phase 1 clinical trial, identified as NCT00536588, which evaluated its safety and tolerability in patients with transitional cell carcinoma of the bladder. The trial enrolled 17 participants.
SCH 721015 with SCH 209702 is a combination therapy that includes SCH 209702 as one of its components. The drug name refers to the combined regimen being studied for bladder cancer.